ATE273979T1 - Xanthinderivate, zwischenprodukte und verwendung zur behandlung von osteoporosis - Google Patents

Xanthinderivate, zwischenprodukte und verwendung zur behandlung von osteoporosis

Info

Publication number
ATE273979T1
ATE273979T1 AT01907784T AT01907784T ATE273979T1 AT E273979 T1 ATE273979 T1 AT E273979T1 AT 01907784 T AT01907784 T AT 01907784T AT 01907784 T AT01907784 T AT 01907784T AT E273979 T1 ATE273979 T1 AT E273979T1
Authority
AT
Austria
Prior art keywords
osteoporosis
treatment
xanthine derivatives
intermediate products
derivatives
Prior art date
Application number
AT01907784T
Other languages
English (en)
Inventor
Guenter Johannes Billen
Yamina Bouali
Francois Nique
Yusuke Satoh
Jean-Paul Vevert
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE273979T1 publication Critical patent/ATE273979T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01907784T 2000-02-15 2001-02-14 Xanthinderivate, zwischenprodukte und verwendung zur behandlung von osteoporosis ATE273979T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0001845A FR2804958B1 (fr) 2000-02-15 2000-02-15 Derives de xanthine, leur procede de preparation et les intermediaires de ce procede, leur application comme medicament et les compositions pharmaceutiques les renfermant
PCT/FR2001/000420 WO2001060824A1 (fr) 2000-02-15 2001-02-14 Derives de xanthine, intermediaires et application au traitement de l'osteoporose

Publications (1)

Publication Number Publication Date
ATE273979T1 true ATE273979T1 (de) 2004-09-15

Family

ID=8847004

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01907784T ATE273979T1 (de) 2000-02-15 2001-02-14 Xanthinderivate, zwischenprodukte und verwendung zur behandlung von osteoporosis

Country Status (9)

Country Link
EP (1) EP1257552B1 (de)
AT (1) ATE273979T1 (de)
AU (1) AU2001235668A1 (de)
DE (1) DE60104986T2 (de)
DK (1) DK1257552T3 (de)
ES (1) ES2227134T3 (de)
FR (1) FR2804958B1 (de)
PT (1) PT1257552E (de)
WO (1) WO2001060824A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004009091A1 (en) 2002-06-17 2004-01-29 Glaxo Group Limited Purine derivatives as liver x receptor agonists
MX2010007419A (es) 2008-01-04 2010-11-12 Intellikine Inc Ciertas entidades quimicas, composiciones y metodos.
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
ES2637113T3 (es) 2011-01-10 2017-10-10 Infinity Pharmaceuticals, Inc. Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
AU2013337717B2 (en) 2012-11-01 2018-10-25 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
WO2015003881A1 (en) * 2013-07-08 2015-01-15 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
SG11201811237WA (en) 2016-06-24 2019-01-30 Infinity Pharmaceuticals Inc Combination therapies
CN109503583A (zh) * 2018-12-14 2019-03-22 南京纽邦生物科技有限公司 1,7-二甲基黄嘌呤及其中间体的制备方法、中间体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2130138T3 (es) * 1990-10-18 1999-07-01 Kyowa Hakko Kogyo Kk Derivado de xantina.
AU692104B2 (en) * 1995-05-19 1998-05-28 Darwin Discovery Limited Xanthines and their therapeutic use
JPH09169665A (ja) * 1995-12-21 1997-06-30 Kenichi Miyamoto 骨粗鬆症治療剤
ES2185837T3 (es) * 1996-06-07 2003-05-01 Hoechst Ag Utilizacion de derivados de teofilina para el tratamiento y la profilaxis de las enfermedades de choque, nuevos compuestos de xantina y procedimientos para su produccion.
GB9703044D0 (en) * 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
JPH1192379A (ja) * 1997-07-24 1999-04-06 Kunio Takaoka 骨疾患の予防または治療剤

Also Published As

Publication number Publication date
EP1257552A1 (de) 2002-11-20
DE60104986T2 (de) 2005-08-25
DK1257552T3 (da) 2004-12-20
ES2227134T3 (es) 2005-04-01
EP1257552B1 (de) 2004-08-18
FR2804958A1 (fr) 2001-08-17
WO2001060824A1 (fr) 2001-08-23
PT1257552E (pt) 2005-01-31
AU2001235668A1 (en) 2001-08-27
DE60104986D1 (de) 2004-09-23
FR2804958B1 (fr) 2005-07-08

Similar Documents

Publication Publication Date Title
LU92146I2 (fr) Dasatinib et ses sels pharmaceutiquement acceptables
FI913478A0 (fi) Diazinderivat.
HUP9802859A2 (hu) Acil-amino-szalicilsav-amid-származékok és alkalmazásuk peszticidként
BG101582A (bg) Пиперазинови производни, съдържащите ги лекарствени форми, приложението им и метод за тяхното получаване
ATE235459T1 (de) Derivate von aminosäuren, sie enthaltende pharmazeutische zusammensetzungen sowie deren herstellunsgverfahren
AR024390A1 (es) Nuevos compuestos
ATE202702T1 (de) Verwendung von oestrogenagonisten und - antagonisten zur herstellung eines medikaments zur behandlung von atherosklerose, unabhängig von lipidsenkung
ATE103812T1 (de) Zusammensetzung zur behandlung von ischaemischen stoerungen in organen.
ATE302778T1 (de) N-substituierte 4-aminopteridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE69607650D1 (de) 2,3,5-trimethyl-hydroxyanilid-derivative, ihre herstellung und ihre theraoeutische verwendung
ATE273979T1 (de) Xanthinderivate, zwischenprodukte und verwendung zur behandlung von osteoporosis
FI944823A0 (fi) Galantamiinijohdannaisia, menetelmä niiden valmistamiseksi ja niiden käyttö lääkeaineissa
FI894061A0 (fi) Menetelmä lääkeaineina käyttökelpoisten , -disubstituoitujen N-sykloalkyylialkyylibentsyyliamiinien valmistamiseksi ja niiden synteesivälituotteita
DK0450420T3 (da) Heterocyclisk substituerede dihydropyridiner, fremgangsmåde til deres fremstilling og deres anvendelse i lægemidler
MXPA05014068A (es) Dicetopiperazinas sustituidas y su uso como antagonistas de oxitocina.
ATE308533T1 (de) Zwischenprodukt und verfahren zur teilsynthese von paclitaxel und dessen analogen
BR9610175A (pt) Composto processo de preparação do composto composição farmacêutica e utilização do composto
DK0625153T3 (da) Nyt isoindolinonderivat, dets fremstilling og farmaceutiske præparater med et indhold deraf
ZA939118B (en) Processes for preparing 2-cyano-3-hydroxy-propenamides and pharmaceutical compositions containing them
BG105923A (en) Novel morpholine derivatives, method for the production thereof and pharmaceutical preparations containing said derivatives
DE69917668D1 (de) Substanz gm-95, verfahren zu ihrer herstellung und ihre verwendung
DE59606725D1 (de) Substituierte phenylamidine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE69002340D1 (de) Pyrimidin-derivate, 2-(4-(alpha-heteroaryl-alpha-aryl-(alpha-alkyl)-methoxy)-butyl)-1-piperazinyl) mit serotoninergischer wirkung.
ATE186214T1 (de) Verwendung von rosmanolderivaten zur herstellung von antiradikalischen und/oder antilipoperoxidativen und/oder hepatotropen arzneistoffen
PT99280A (pt) Processo de preparacao de derivados do indolo e de composicoes farmaceuticas

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1257552

Country of ref document: EP